Differential Activity of Nivolumab, Pembrolizumab and...

PLoS ONE 2015 / 6 Vol. 10; Iss. 6

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

Carbognin, Luisa, Pilotto, Sara, Milella, Michele, Vaccaro, Vanja, Brunelli, Matteo, Caliò, Anna, Cuppone, Federica, Sperduti, Isabella, Giannarelli, Diana, Chilosi, Marco, Bronte, Vincenzo, Scarpa, A
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
10
Language:
english
Journal:
PLOS ONE
DOI:
10.1371/journal.pone.0130142
Date:
June, 2015
File:
PDF, 1.59 MB
english, 2015
Conversion to is in progress
Conversion to is failed